Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Current Assets (2020 - 2025)

Historic Current Assets for Janux Therapeutics (JANX) over the last 6 years, with Q3 2025 value amounting to $998.1 million.

  • Janux Therapeutics' Current Assets rose 4979.06% to $998.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $998.1 million, marking a year-over-year increase of 4979.06%. This contributed to the annual value of $1.0 billion for FY2024, which is 19597.5% up from last year.
  • Janux Therapeutics' Current Assets amounted to $998.1 million in Q3 2025, which was up 4979.06% from $1.0 billion recorded in Q2 2025.
  • Janux Therapeutics' Current Assets' 5-year high stood at $1.0 billion during Q4 2024, with a 5-year trough of $309.3 million in Q2 2023.
  • For the 5-year period, Janux Therapeutics' Current Assets averaged around $552.5 million, with its median value being $383.3 million (2021).
  • As far as peak fluctuations go, Janux Therapeutics' Current Assets surged by 224727.31% in 2021, and later tumbled by 1361.85% in 2023.
  • Over the past 5 years, Janux Therapeutics' Current Assets (Quarter) stood at $377.0 million in 2021, then fell by 11.82% to $332.4 million in 2022, then grew by 5.05% to $349.2 million in 2023, then surged by 195.97% to $1.0 billion in 2024, then decreased by 3.44% to $998.1 million in 2025.
  • Its Current Assets was $998.1 million in Q3 2025, compared to $1.0 billion in Q2 2025 and $1.0 billion in Q1 2025.